Antithrombin in sepsis revisited

Critical Care

Volumn 9, Issue 6, 2005, Pages 624-625

  Levi, Marcel ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; HEPARIN;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; BLOOD CLOTTING; CLINICAL TRIAL; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG USE; HUMAN; MORTALITY; NOTE; PRIORITY JOURNAL; SEPSIS; SUBSTITUTION THERAPY;

ANTICOAGULANTS; ANTITHROMBINS; CRITICAL CARE; CRITICAL ILLNESS; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; SEPSIS; TREATMENT OUTCOME;

EID: 31744444068     PISSN: 13648535     EISSN: None     Source Type: Journal    
DOI: 10.1186/cc3819     Document Type: Note

References (14)

1. Kountchev J, Bijuklic K, Belimann R, Wiedermann CJ, Joannidis M: Reduction of D-dimer levels after therapeutic administration of antithrombin in acquired antithrombin deficiency of severe sepsis. Crit Care 2005, 9:R596-R600.
2. Esmon CT: Role of coagulation inhibitors in inflammation. Thromb Haemost 2001, 86:51-56.
3. Levi M, de Jonge E, van der Poll T: Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit Care Med 2001, 29(Suppl 7):S90-94.
4. Mesters RM, Mannucci PM, Coppola R, Keller T, Ostermann H, Kienast J: Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood 1996, 88:881-886.
5. Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Narey P, Lestavel P: Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies [see comments]. Chest 1992, 101:816-823.
6. Minnema MC, Chang AC, Jansen PM, Lubbers YT, Pratt BM, Whittaker BG, Taylor FB, Hack CE, Friedman B: Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood 2000, 95:1117-1123.
7. Levi M, van der Poll T, Buller HR: Bidirectional relation between inflammation and coagulation. Circulation, 109:2698-2704.
8. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709.
9. Levi M, ten Cate H, van der Poll T: Disseminated intravascular coagulation: State of the art. Thromb Haemost 1999, 82:695-705.
10. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Penzes I, Kubler A, Knaul S, et al.: Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. J Am Med Assoc 2001, 286:1869-1878.
11. Blauhut B, Kramar H, Vinazzer H, Bergmann H: Substitution of antithrombin III in shock and DIC: a randomized study. Thromb Res 1985, 39:81-89.
12. Bernard GR, Ely EW, Wright TJ, Stasek JE, Russell JA, Norris PE, Yau SB, Helterbrand JD: Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 2001, 29:2051-2059.
13. Taylor FBJ, Toh CH, Hoots WK, Wada H, Levi M: Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001, 86:1327-1330.
14. Dhainaut JF, Yan SB, Joyce DE, Petilla V, Busson BR, Brauelt JT, Saudin D, Levi M: Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004, 2:1924-1933.